Scarica l'app Stockscreener
4.695
2.39%
-0.115
Dopo l'orario di chiusura:
4.75
0.055
+1.17%
Precedente Chiudi:
$4.81
Aprire:
$4.83
Volume 24 ore:
493.02K
Relative Volume:
0.36
Capitalizzazione di mercato:
$130.78M
Reddito:
$675.00K
Utile/perdita netta:
$-39.95M
Rapporto P/E:
-2.2831
EPS:
-2.0564
Flusso di cassa netto:
$-28.67M
1 W Prestazione:
-2.19%
1M Prestazione:
-14.17%
6M Prestazione:
-29.40%
1 anno Prestazione:
+25.53%
Intervallo 1D:
$4.66
$4.85
Intervallo di 1 settimana:
$4.62
$4.97
Portata 52W:
$3.75
$8.74
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
Nome
Unicycive Therapeutics Inc
Settore
Industria
Telefono
650-384-0642
Indirizzo
1975 W. EL CAMINO REAL, SUITE 204, MOUNTAIN VIEW
Compare UNCY vs VRTX, REGN, MRNA, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
4.695 | 130.78M | 675.00K | -39.95M | -28.67M | -2.0564 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-21 | Iniziato | Guggenheim | Buy |
| 2024-04-04 | Iniziato | Piper Sandler | Overweight |
Unicycive Therapeutics Inc Borsa (UNCY) Ultime notizie
Faruqi & Faruqi, LLP Urges Unicycive Therapeutics, Inc. (UNCY) Investors to Seek Counsel Before the November 2, 2026 Lead Plaintiff Deadline in the Securities Class Action - TMX Newsfile
Shareholders of Unicycive Therapeutics, Inc. (UNCY): Protect Your Rights Before November 2, 2026 – Contact Levi & Korsinsky - ACCESS Newswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionUNCY - TMX Newsfile
UNCY Stockholders Have Rights – If You Lost Money Investing - GlobeNewswire
UNCY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Unicycive Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
UNCY Stock Clocks Worst Day In A Year — Analysts Keep Buy Ratings Despite ‘5-12 Month Delay’ In Drug Approval - Stocktwits
UNCY Stock Crashed 45% Today – Why Did FDA Reject Its Kidney Disease NDA For A Second Time? - Stocktwits
Levi & Korsinsky Urges Unicycive Therapeutics, Inc. (UNCY) Shareholders to Act Before Lead Plaintiff Deadline November 2, 2026 - ACCESS Newswire
Class Action Lawsuit Alert: Levi & Korsinsky Reminds Unicycive Therapeutics, Inc. (UNCY) Investors of November 2, 2026 Deadline - ACCESS Newswire
Lost Money on Unicycive Therapeutics, Inc. (UNCY)? Join Class Action Before November 2, 2026Contact Levi & Korsinsky - ACCESS Newswire
Class Action Filed Against Unicycive Therapeutics, Inc. (UNCY) Over Securities ViolationsContact Levi & Korsinsky Today - accessnewswire.com
Kaplan Fox Encourages Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Investors to Contact the Firm Before the Deadline on November 2, 2026 - The Globe and Mail
Bronstein, Gewirtz & Grossman LLC Urges Unicycive - GlobeNewswire
UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, Inc. Securities Class ActionContact SueWallSt - PR Newswire
Securities Class Action Lawsuit Filed Against Unicycive Therapeutics, Inc. (UNCY)Levi & Korsinsky Represents Shareholders - ACCESS Newswire
UNCY Investor Alert: Unicycive Therapeutics, Inc. Securities Class Action NoticeContact Levi & Korsinsky - AOL.ca
Did You Lose Money on Unicycive Therapeutics, Inc. (UNCY)? Levi & Korsinsky Urges Investors to Act Before November 2, 2026 - ACCESS Newswire
UNCY EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Unicyci - The National Law Review
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Unicycive - GlobeNewswire
Kaplan Fox Encourages Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Investors to Contact the Firm Before the Lead Plaintiff Deadline on November 2, 2026 - NewMediaWire
UNCY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Unicycive Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
Kaplan Fox Encourages Unicycive Therapeutics, Inc. (NASDAQ: UNCY) - The National Law Review
UNCY stock rises after a class action filing and a reverse split - ad-hoc-news.de
Deadline Alert: Unicycive Therapeutics, Inc. (UNCY) - GlobeNewswire
Levi & Korsinsky Notifies Unicycive Therapeutics, Inc. (UNCY) Shareholders of Class Action Lawsuit and November 2, 2026 Deadline - ACCESS Newswire
Unicycive Therapeutics, Inc.(NasdaqCM: UNCY) added to S&P Global BMI Index - marketscreener.com
UNCY SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Unicycive Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Unicycive Therapeutics stock holds at USD 4.80 - AD HOC NEWS
UNCY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026 - TMX Newsfile
UNCY SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Unicycive Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Robbins LLP Urges UNCY Stockholders Who Lost Money Investing in Unicycive Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action - Business Wire
Contact Levi & Korsinsky by November 2, 2026 to Join Class Action Against Unicycive Therapeutics, Inc. (UNCY) - ACCESS Newswire
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
UNCY SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
ROSEN, A LEADING NATIONAL FIRM, Encourages Unicycive - GlobeNewswire
DEADLINE ALERT for YSS, HIMS, UNCY, and PZZA: The Law - GlobeNewswire
UNCY SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026 - TMX Newsfile
Unicycive Therapeutics, Inc.'s (NASDAQ:UNCY) Profit Outlook - simplywall.st
Unicycive Therapeutics stock faces class action pressure after manufacturing oversight claims - AD HOC NEWS
UNCY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Unicycive Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Bronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - WBOC TV
UNCY Shareholder Alert: Unicycive Therapeutics, Inc. Securities Class Action LawsuitInvestors Should Contact SueWallSt - PR Newswire
Kirby McInerney LLP Alerts Investors Who Acquired Unicycive - GlobeNewswire
UNCY DEADLINE: Levi & Korsinsky Reminds Unicycive Therapeutics, Inc. Investors of Upcoming Securities Class Action Deadline - PR Newswire
UNCY SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Unicycive Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionUNCY - The Conway Daily Sun
UNCY: Regulatory approval awaits only a vendor inspection, with launch readiness and funding secured - TradingView
Robbins LLP is Investigating Allegations that Unicycive Therapeutics, Inc. Failed to Properly Inspect its Third-Party Vendor's Manufacturing Facility to Ensure it Resolved the FDA's Previously Noted Deficiencies - The Globe and Mail
Unicycive Therapeutics Inc Azioni (UNCY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):